These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26987984)

  • 1. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study.
    Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Holtzman C; Harrison LH; Zansky SM; Rosen JB; Reingold A; Scherzinger K; Thomas A; Guevara RE; Motala T; Eason J; Barnes M; Petit S; Farley MM; McGee L; Jorgensen JH; Whitney CG
    Lancet Respir Med; 2016 May; 4(5):399-406. PubMed ID: 26987984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
    Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
    Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
    Domínguez Á; Ciruela P; Hernández S; García-García JJ; Soldevila N; Izquierdo C; Moraga-Llop F; Díaz A; F de Sevilla M; González-Peris S; Campins M; Uriona S; Martínez-Osorio J; Solé-Ribalta A; Codina G; Esteva C; Planes AM; Muñoz-Almagro C; Salleras L
    PLoS One; 2017; 12(8):e0183191. PubMed ID: 28806737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.
    Domingues CM; Verani JR; Montenegro Renoiner EI; de Cunto Brandileone MC; Flannery B; de Oliveira LH; Santos JB; de Moraes JC;
    Lancet Respir Med; 2014 Jun; 2(6):464-71. PubMed ID: 24726406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.
    Whitney CG; Pilishvili T; Farley MM; Schaffner W; Craig AS; Lynfield R; Nyquist AC; Gershman KA; Vazquez M; Bennett NM; Reingold A; Thomas A; Glode MP; Zell ER; Jorgensen JH; Beall B; Schuchat A
    Lancet; 2006 Oct; 368(9546):1495-502. PubMed ID: 17071283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.
    Andrews NJ; Waight PA; Burbidge P; Pearce E; Roalfe L; Zancolli M; Slack M; Ladhani SN; Miller E; Goldblatt D
    Lancet Infect Dis; 2014 Sep; 14(9):839-46. PubMed ID: 25042756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.
    Savulescu C; Krizova P; Lepoutre A; Mereckiene J; Vestrheim DF; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Varon E; Cotter S; Winje BA; Munoz-Almagro C; Garcia L; Castilla J; Smith A; Henriques-Normark B; Celentano LP; Hanquet G;
    Lancet Respir Med; 2017 Aug; 5(8):648-656. PubMed ID: 28359798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study.
    Guevara M; Barricarte A; Torroba L; Herranz M; Gil-Setas A; Gil F; Bernaola E; Ezpeleta C; Castilla J;
    Euro Surveill; 2016; 21(14):. PubMed ID: 27103428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic.
    Tomczyk S; Lessa FC; Sánchez J; Peña C; Fernández J; Gloria Carvalho M; Pimenta F; Cedano D; Whitney CG; Verani JR; Coradin H; Garib Z; De Oliveira LH; Feris-Iglesias J
    BMC Infect Dis; 2018 Apr; 18(1):152. PubMed ID: 29609548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
    Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM
    Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.
    Kaplan SL; Barson WJ; Lin PL; Romero JR; Bradley JS; Tan TQ; Hoffman JA; Givner LB; Mason EO
    Pediatr Infect Dis J; 2013 Mar; 32(3):203-7. PubMed ID: 23558320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
    Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Lexau C; Bennett NM; Petit S; Zansky SM; Harrison LH; Reingold A; Miller L; Scherzinger K; Thomas A; Farley MM; Zell ER; Taylor TH; Pondo T; Rodgers L; McGee L; Beall B; Jorgensen JH; Whitney CG
    Lancet Infect Dis; 2015 Mar; 15(3):301-9. PubMed ID: 25656600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany.
    van der Linden M; Falkenhorst G; Perniciaro S; Fitzner C; Imöhl M
    PLoS One; 2016; 11(8):e0161257. PubMed ID: 27526117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
    Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
    Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.